CARLINA Technologies is a contract service-based biotechnology company specialized in the development of nanomedicines for human and animal health using innovative proprietary controlled drug delivery platforms as well as off-patent drug delivery systems.
CARLINA Technologies will help you to design, develop and manufacture the most unique and appropriate delivery system according to the nature of your active ingredient, administration route used and therapeutic target.
Controlled drug delivery platforms and specific know-how are provided to you, to address pharmacological issues of active ingredients without affecting their chemical integrity.
Olivier Meyer has a scientific background by training. He obtained his Ph.D. in pharmaceutical sciences from the University of Paris-Sud, France, in 1995.
The same year, Dr. Meyer joined the Cancer Research Institute of the University of California at San Francisco, as a post-doctoral fellow in the laboratory of Pr. Demetrios Papahadjopoulos who was one of the co-inventor of the pioneered anticancer nanomedicine product Doxil®/Caelyx™. During this period, Olivier Meyer had developed a number of innovative lipid-based systems for the delivery of anti-cancer drugs, contrast agents and therapeutic biologics.
During his more than 20 years of professional experience, Olivier Meyer occupied various R&D and corporate top management positions in biotechnology companies and the pharmaceutical industry both in France and Canada.
Olivier Meyer has been awarded by the French Ministry of Research in 2010 for the creation and the development of innovative technology companies and co-founded CARLINA Technologies the same year.
Carl Simonsson obtained his Ph.D. in 2011 from the University of Gothenburg, Sweden. His research work done in the Department of Chemistry and Molecular Biology was focused on new insights in contact allergy and drug delivery.
After being a teaching assistant for more than five years, Dr. Simonsson joined the U1066 INSERM Research Unit at the University of Angers to continue his research work in developing innovative drug nanocarrier-based formulations for proteins and peptides.
He finally joined CARLINA’s team as R&D Project Leader and Formulation Development Manager in 2017.
Chairman, CEO CARLINA Technologies
Member, CEO Takabio
Member, Business Analyst at GO Capital
Member, CEO Hoolders-Carlina